Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Agent Capital
AddedFeb 13, 2024
UpdatedJul 16, 2026
Agent Capital

Agent Capital

Operating

Agent Capital: A healthcare-focused venture capital firm investing in innovative solutions for unmet patient needs.

Location
Waltham, MA, US
Founded
2016
Firm
Compare
Portfolio
Employees

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
Cantai Therapeutics
Cantai Therapeutics

Total Raised

$700k

Rounds

1

Seed$700kNovember 2023
ViTToria Biotherapeutics
ViTToria Biotherapeutics

Total Raised

$25M

Rounds

2

Series Unknown$15MNovember 2023
Seed$10MJune 2022
Jana Care
Jana Care

Total Raised

$18.7M

Rounds

3

Series B$6MNovember 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Foresight Diagnostics
Foresight Diagnostics

Total Raised

$71.3M

Rounds

4

Series B$58.8MApril 2023
Orbital Therapeutics
Orbital Therapeutics

Total Raised

$270M

Rounds

2

Series A$270MApril 2023
Palvella Therapeutics
Palvella Therapeutics
Acquired

Total Raised

$106.8M

Rounds

6

Series D$37.7MJanuary 2023
Series C$45MMay 2020
Carisma Therapeutics
Carisma Therapeutics
Public

Total Raised

$151.9M

Rounds

8

Series C$30MSeptember 2022
Series B$12MMarch 2021
Series B$47MJanuary 2021
Carbon Biosciences
Carbon Biosciences

Total Raised

$38M

Rounds

1

Series A$38MJune 2022
Affini-T Therapeutics
Affini-T Therapeutics

Total Raised

$175M

Rounds

1

Series Unknown$175MMarch 2022
Cyrus Biotechnology
Cyrus Biotechnology

Total Raised

$46.8M

Rounds

9

Series B$18MDecember 2021
Immunitas Therapeutics
Immunitas Therapeutics

Total Raised

$97M

Rounds

2

Series B$58MAugust 2021
Interius BioTherapeutics
Interius BioTherapeutics

Total Raised

$103M

Rounds

3

Series A$76MMay 2021
Series Unknown$5.5MMarch 2020
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
Mediar Therapeutics
Mediar Therapeutics

Total Raised

$145.6M

Rounds

4

SeedMarch 2021
Metagenomi
Metagenomi

Total Raised

$457M

Rounds

7

Series A$75MNovember 2020
Series A$26.4MAugust 2019
Pliant Therapeutics
Pliant Therapeutics
Public

Total Raised

$694.9M

Rounds

6

Series C$100.4MMarch 2020